The first group should not be addressed to anti-EGFR MoAb treatments based on the sole primary tumour evaluation, but eventually, it may benefit from these targeted therapies because of the presence of EGFR gene CNG in metastatic sites. This evidence concerns the gene EGFR and neoplasm.